Skip to content

Study · Non-randomized trial · n = 22 · 1995

1 result

The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.

Ramirez G, Herrera R, Pineda D, Bittle PA, Rabb HA, Bercu BB

Clinical endocrinology1 Jul 1995Cited by 11 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialActivity measurement

    In men born and living at high altitude, the GH response to intravenous GHRH(1-29) was exaggerated compared with men living at sea level.

    In plain wordsIn men living at high altitude, growth hormone rose more after GHRH(1-29) than in men living at sea level.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH response to GHRH in high-altitude versus sea-level men
    Study

    n = 22

    Comparator
    Men living at sea level
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    GH response to GHRH in HA men was exaggerated compared to SL men, and IGF-I concentration was also significantly increased in the presence of normal levels of IGFBP-3.
    2 context sentences
    Summary · context
    Growth hormone releasing hormone (Geref 1-29) 1 microgram/kg, TRH 500 micrograms, GHRH 100 micrograms and ovine corticotrophin releasing hormone (oCRH) 1 microgram/kg were simultaneously administered intravenously
    Summary · context
    12 born and raised in the city of Pasto, Colombia, South America, located at an altitude of 2600 m in the southern Colombian Andes (HA group) and 10 men living at sea level (SL) in Tampa, Florida.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.